Clinical Trials Logo

Depression, Unipolar clinical trials

View clinical trials related to Depression, Unipolar.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06094907 Completed - Depressive Disorder Clinical Trials

Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression

Start date: October 9, 2023
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the acute and subacute effects of an inhaled N, N-Dimethyltryptamine (DMT) in patients with partial response in depression.

NCT ID: NCT05168735 Completed - Clinical trials for Depression, Unipolar

Ketamine + Mindfulness for Depression

Start date: February 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises in conjunction with the infusion. Investigators will test whether the conjunction of ketamine + mindfulness enhances the reductions in depression following a single ketamine infusion.

NCT ID: NCT04978220 Completed - Insomnia Clinical Trials

Mental and Psychological Problems and Insomnia Disorder of Medical Staff in Hospital With Infected COVID-19 Patients

Start date: June 27, 2020
Phase:
Study type: Observational

The objective of this study is to clarify the severity of psychological problems and insomnia and the two's relationship with time of hospital medical staff in hospital where its staff are infected with COVID-19.

NCT ID: NCT04916548 Completed - Clinical trials for Depression, Unipolar

Repeated Neurocognitive Measurements in Depressed Patients

Start date: September 16, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.

NCT ID: NCT04159285 Completed - Clinical trials for Treatment Resistant Depression

Psychotherapeutic Augmentation of Brain Stimulation Effects

PAUSE
Start date: January 5, 2019
Phase: N/A
Study type: Interventional

This study aims to investigate effectiveness and feasability of a 15-week group psychotherapeutic intervention as continuation treatment after electroconvulsive therapy in severely depressed patients. Feasibility and acceptance of the half-open manualized CBT intervention are assessed. Depressive symptoms, quality of life and emotion regulation skills will be assessed before ECT treatment, before and after the 15-week group CBT intervention and at a 6 months follow-up after treatment end and compared to depressed patients treated with ECT who did not partake in group CBT. Moreover, patients will attend two indidivual pre-group sessions with one of the group therapist and one individual post-group session

NCT ID: NCT04121091 Completed - Anhedonia Clinical Trials

Pramipexole to Target "Anhedonic Depression"

PILOT-PRAXOL
Start date: October 4, 2019
Phase: Phase 2
Study type: Interventional

The heterogeneity of depression suggests that different neurocircuits and pathophysiological mechanisms are involved. Anhedonia - the inability to experience pleasure from, or the lack of motivation to carry out, usually enjoyable activities - is an endophenotype within the depression spectrum, with a distinct pathophysiology of dopaminergic mesolimbic projections. Anhedonia is common in depression and associated with treatment resistance. Pramipexole, an agonist to the dopamine -receptor 3, is an established treatment of Parkinson's disease. Based on its mechanism of action, pramipexole might be efficacious in a subtype of depression characterized by anhedonia and lack of motivation - symptoms linked to dopaminergic hypofunction. In this proof-of-concept pilot study the investigators test the anti-anhedonic and antidepressant effects of add-on pramipexole using an "enriched population study design" including only depressed patients with significant anhedonia. To understand the neurobiology of anhedonia in depression and to identify treatment predictors, the investigators also do assessments of anhedonia-related neurocircuitry using (f)MRI and blood biomarkers.

NCT ID: NCT03990389 Completed - Clinical trials for Depression, Postpartum

Tracking Depression Symptoms With a Health Chatbot

Start date: February 20, 2019
Phase: N/A
Study type: Interventional

The goal of this research is to bridge a significant "effectiveness" gap in the treatment of depression. The investigators have developed a chatbot which will assist in performing measurement-based care (MBC) via Facebook Messenger. Participants will be randomized to either Usual Care or Usual Care with additional Chatbot Care.

NCT ID: NCT03906175 Completed - Clinical trials for Depression, Unipolar

Whole-body Hyperthermia for Mild to Moderate Depressive Disorder

HYPE1
Start date: June 11, 2019
Phase: N/A
Study type: Interventional

The primary aim of this study is to investigate the effectiveness of whole-body hyperthermia in comparison to wait list on depressive symptom severity in patients with mild to moderate depressive disorder currently not under psychotherapeutic or antidepressant drug treatment. Secondary aims included further quality of life outcomes, immunological parameters, and tolerability/safety of the hyperthermia.

NCT ID: NCT03906149 Completed - Clinical trials for Depression, Unipolar

Whole-body Hyperthermia for Moderate to Severe Depressive Disorder

HYPE2
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The primary aim of this study is to investigate the effectiveness of whole-body hyperthermia in addition to standard medical care in comparison to standard medical care alone on depressive symptom severity in patients with moderate to severe depressive disorder. Secondary aims included further quality of life outcomes, immunological parameters, and tolerability/safety of the hyperthermia.

NCT ID: NCT03556735 Completed - Clinical trials for Depression, Unipolar

Pulsed Electro Magnetic Fields (PEMF) in Depression

PEMF
Start date: September 2016
Phase: N/A
Study type: Interventional

PEMF (Pulsed Electro Magnetic Fields) therapy has been used to stimulate bone repair in non-union since the 1970s. This is an accepted use, which has been approved by the Food and Drug Administration in the US. The mode of action of PEMF is based on creating small electrical fields in tissue and thereby promoting healing. Besides it has been shown that PEMF enhance regeneration of nerve fibers exposed to a lesion For treatment of depression the PEMF equipment, which are provided by the company Re5 A/S, consists of a 220 V impulse generator that creates electrical impulses and an applicator which consists of an electrical cable connected to a helmet on which there are 7 electrical coils on the inside. In comparison with the rTMS (Transcranial Magnetic Stimulation) equipment, which uses stimuli approaching neuronal firing level, the PEMF fields in human is very much lower.